Zant AE, Figueroa XA, Paulson CP, Wright JK, et al.
Undersea & hyperbaric medicine : journal of the Undersea and Hyperbaric Medical Society, Inc. Date of publication 2022 Jul 1;volume 49(3):333-339.
1. Undersea Hyperb Med. 2022 Third Quarter;49(3):333-339. doi:
10.22462/05.06.2022.7.
Hyperbaric oxygen therapy to treat lingering COVID-19 symptoms.
Zant AE(1), Figueroa XA(2), Paulson CP(3), Wright JK(4).
Author information:
(1)Hyperbaric Medicine Inc. Fort Walton Beach, Florida U.S.
(2)Unaffiliated, Seattle, Washington U.S.
(3)Magnolia Medical Clinic, Fort Walton Beach, Florida.
(4)Olympic Medical Center, Port Angeles, Washington.
BACKGROUND: SARs-Cov-2 infections can produce prolonged illness and significant
disability. Patients recovering from COVID-19 can have persistent symptoms
leading to long-term morbidity.
METHODS: Six patients with long-lasting (> 30 days) COVID-19 symptoms were
treated with hyperbaric oxygen (HBO2) therapy. All patients were assessed for
symptoms using the ImPACT questionnaire, a muscle and joint pain scale, and a
modified Borg dyspnea scale. Patients were assessed before, during and after
HBO2 treatments.
RESULTS: All patients saw improvements in the measured symptoms to levels that
were the same as pre-infection levels (five of six patients) or had significant
improvement in symptoms (one patient).
CONCLUSION: The results suggest that HBO2 helped to improve symptom scores,
reduce the length of time of symptoms, and improved the quality of life. More
detailed and randomized studies are needed to confirm the results in this
report.
Copyright© Undersea and Hyperbaric Medical Society.
DOI: 10.22462/05.06.2022.7
PMID: 36001566 [Indexed for MEDLINE]
Conflict of interest statement: The authors of this paper declare no conflicts
of interest exist with this submission.
